Use of low dose IL-2 for treating autoimmune—related or inflammatory disorders
The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
1. A method for treating systemic vasculitis, the method comprises administering to a human subject in need thereof an effective amount of repeated doses of interleukin-2 (IL-2), wherein each dose of the IL-2 is between 0.1 MIU/day and 3.5 MIU/day.
2. The method of claim 1 , wherein the subject is administered IL-2 at a dose of 1 MIU/day to 3.5 MIU/day.
3. The method of claim 1 , wherein the subject is administered IL-2 at a dose of 1.5 MIU/day to 3.5 MIU/day.
4. The method of claim 1 , wherein the subject is administered IL-2 at a dose of 0.5 MIU/day to 1.5 MIU/day.
5. The method of claim 1 , wherein the subject is administered IL-2 at a dose of 1.5 MIU/day.
6. The method of claim 1 , wherein the subject is administered des-alanyl-1, serine-125 human interleukin-2.
7. The method of claim 1 , wherein the IL-2 is administered once per day during at least 3 consecutive days.
8. The method of claim 1 , wherein the IL-2 is administered to the subject in a first course of treatment once per day during 3 to 7 days, followed by a maintenance dose given to the subject once a week, once a month, or twice a month.
9. The method of claim 8 , wherein the maintenance dose is administered one to four weeks after the last dose of the first course of treatment.
10. The method of claim 1 , wherein the IL-2 is administered by a subcutaneous route.